KR-20260062924-A - Methods to measure the risk or presence of metabolic dysfunction or age-related diseases

Abstract

The present invention provides a method for detecting the risk or presence of metabolic dysfunction or age-related disease in a subject. The present invention also provides a method for identifying a subject requiring treatment for the risk or presence of metabolic dysfunction or age-related disease.

Inventors

• 할리우아-하우볼드 셀린-리
• 그린우드 카렌
• 후아레즈-살리나스 디나
• 펠로퀸 매튜
• 그레이브스 제시카

Assignees

• 로얄 애니멀 헬쓰, 인크.

Dates

Publication Date

20260507

Application Date

20240620

Priority Date

20230623

Claims (20)

1. A method for promoting health or treating the risk or presence of metabolic dysfunction or age-related disease in a subject, comprising the step of administering a nutraceutical composition or a pharmaceutical composition to a subject, wherein the administration is based on an assessment of the risk or presence of metabolic dysfunction or age-related disease in the subject, and the assessment (a) a step of measuring fatty acid levels in the subject using a high-fidelity fatty acid assay, or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; and (b) a step of evaluating the quality of life, frailty, or multimorbidity of the subject. A method that includes
2. A method for promoting health or treating the risk or presence of metabolic dysfunction or age-related disease in a subject, comprising the step of administering a nutraceutical composition or a pharmaceutical composition to a subject, wherein the administration is based on an assessment of the risk or presence of metabolic dysfunction or age-related disease in the subject, and the assessment (a) a step of measuring fatty acid levels in the subject using a high-fidelity fatty acid assay, or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; or (b) A step of evaluating the quality of life, frailty, or multiple morbidity of the subject. A method that includes
3. A method for increasing lifespan, comprising the step of administering a nutraceutical composition or a pharmaceutical composition to a subject, wherein the treatment of the risk or presence of a metabolic dysfunction or age-related disease in the subject is said to be based on an assessment of the risk or presence of the metabolic dysfunction or age-related disease in the subject, and said assessment (a) a step of measuring fatty acid levels in the subject using a high-fidelity fatty acid assay, or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; and/or (b) A step of evaluating the quality of life, frailty, or multiple morbidity of the subject. A method that includes
4. A method for detecting and/or treating metabolic dysfunction or age-related diseases in a subject, (a) a step of measuring fatty acid levels in the subject using a high-fidelity fatty acid assay, or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; and/or (b) by evaluating the quality of life, frailty, or multiple morbidity of the subject, A step to detect the risk or presence of metabolic dysfunction or age-related diseases A method including
5. A method comprising, in any one of claims 1 to 4, a step of measuring a fatty acid level in a subject and a step of measuring an insulin level in a subject.
6. A method according to any one of claims 1 to 5, wherein the measurement of fatty acid levels and/or serum insulin levels, and the assessment of quality of life, frailty or multiple morbidity provide a correlation for detecting the risk or presence of metabolic dysfunction or age-related disease.
7. As a method for identifying subjects requiring treatment for the risk or presence of metabolic dysfunction or age-related diseases, (a) a step of measuring fatty acid levels in the subject using a high-fidelity fatty acid assay, or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; and/or (b) A step of identifying subjects requiring treatment for age-related diseases by evaluating the quality of life, frailty, or multiple morbidity of the subjects. A method including
8. A method according to claim 7, comprising the steps of measuring fatty acid levels within a subject and measuring insulin levels within a subject.
9. A method according to claim 7 or 8, wherein the measurement of fatty acid levels and/or insulin levels and the assessment of quality of life provide a correlation for detecting the risk or presence of metabolic dysfunction or age-related disease.
10. A method according to any one of claims 1 through 9, wherein the quality of life, frailty, or multiple morbidity is measured by the health-related quality of life (HRQL) or the Canine Frailty Index (CFI).
11. As a health screening method for subjects, A step of measuring a fatty acid level within a subject, wherein the fatty acid level is measured by using a high-fidelity fatty acid assay, or A step of measuring an insulin level within a subject, wherein the insulin level is measured by using a high-fidelity insulin assay. Includes, A method in which the above-mentioned subject is a companion mammal.
12. A method according to claim 11, further comprising the step of evaluating the subject's quality of life as measured by health-related quality of life (HRQL), or the subject's senility or multiple morbidity using the Canine Senility Index (CFI).
13. A method according to paragraph 11 or 12 in which the subject has a risk or presence of metabolic dysfunction or age-related disease.
14. A method according to any one of claims 1 to 13, further comprising the step of comparing a fatty acid level in a subject with a predetermined fatty acid level, or the step of comparing an insulin level in a subject with a predetermined insulin level.
15. A method according to any one of claims 3 to 14, further comprising the step of promoting or maintaining the health of a subject by administering a nutraceutical composition to the subject.
16. A method according to claim 15, wherein the nutraceutical composition comprises quercetin, azela oil phosphatidylcholine, or 4-oxodocosahexaenoic acid.
17. A method according to any one of claims 3 to 9, 13 and 14, further comprising the step of treating the risk or presence of metabolic dysfunction or age-related disease in a subject by administering a pharmaceutical composition to the subject.
18. In claim 17, a method wherein the pharmaceutical composition comprises rosiglitazone, lobeglitazone, or a combination thereof.
19. A method according to any one of claims 1 to 18, wherein the high-fidelity fatty acid assay is a gas chromatography-mass spectrometry (GCMS) assay, an ultra-high performance liquid chromatography (UPLC) assay, or a liquid chromatography-mass spectrometry (LCMS) assay.
20. In paragraph 19, a method in which the high-fidelity fatty acid assay is a GCMS assay.

Description

Methods to measure the risk or presence of metabolic dysfunction or age-related diseases Cross-reference of related applications This application claims the benefit of priority for U.S. provisional application No. 63/509,964, filed June 23, 2023 and U.S. provisional application No. 63/602,871, filed November 27, 2023, the entire contents of which are respectively incorporated herein by reference. Background Technology Chronological age is well understood to be the single greatest risk factor for almost all major causes of mortality and morbidity in living organisms, including humans and companion dogs. Even before observable diseases develop, the physiological and metabolic functions of organ systems and tissues progressively decline throughout life. Consequently, there remains an unmet demand for safe and effective products and methods to promote longevity and extend lifespan, as well as for methods to measure the decline in systemic physiological and metabolic functions. Background Technology Chronological age is well understood to be the single greatest risk factor for almost all major causes of mortality and morbidity in living organisms, including humans and companion dogs. Even before observable diseases develop, the physiological and metabolic functions of organ systems and tissues progressively decline throughout life. Therefore, there remains an unmet demand for safe and effective products and methods to promote longevity and extend lifespan, as well as for methods to measure the decline in systemic physiological and metabolic functions. In some embodiments, a method is provided for promoting health in a subject or treating the risk or presence of metabolic dysfunction or age-related disease, comprising the step of administering a nutraceutical composition or a pharmaceutical composition to a subject, wherein the administration is based on an assessment of the risk or presence of metabolic dysfunction or age-related disease in the subject, and the assessment comprises: (a) measuring fatty acid levels in the subject using a high-fidelity fatty acid assay or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; and (b) assessing the quality of life, frailty, or multimorbidity of the subject. In some embodiments, a method is provided for promoting health in a subject or treating the risk or presence of metabolic dysfunction or age-related disease, comprising the step of administering a nutraceutical composition or a pharmaceutical composition to a subject, wherein the administration is based on an assessment of the risk or presence of metabolic dysfunction or age-related disease in the subject, and the assessment comprises: (a) measuring fatty acid levels in the subject using a high-fidelity fatty acid assay or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; or (b) assessing the quality of life, senility, or multiple morbidity of the subject. In some embodiments, a method for extending lifespan, comprising treating a metabolic dysfunction or the risk or presence of age-related disease in a subject, is provided, comprising the step of administering a nutraceutical composition or a pharmaceutical composition to a subject, wherein the administration is based on an assessment of the risk or presence of a metabolic dysfunction or age-related disease in the subject, and the assessment comprises: (a) measuring fatty acid levels in the subject using a high-fidelity fatty acid assay or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; and/or (b) assessing the quality of life, senility, or multiple morbidity of the subject. In some embodiments, a method for detecting and/or treating metabolic dysfunction or age-related disease in a subject is provided, comprising: (a) measuring fatty acid levels in the subject using a high-fidelity fatty acid assay or measuring insulin levels and/or insulin sensitivity in the subject using a high-fidelity insulin assay; and/or (b) evaluating the quality of life, senility, or multiple morbidity of the subject. In some embodiments, the method comprises the steps of measuring fatty acid levels within a subject and measuring insulin levels within a subject. In some embodiments, the measurement of fatty acid levels and/or insulin levels in biological media (whole blood, serum, plasma, CSF, synovial fluid, urine, feces, saliva, and tissue homogenates including muscle, liver, heart, pancreas, and brain) and the assessment of quality of life, frailty, or multiple morbidity provide correlations for detecting the risk or presence of metabolic dysfunction or age-related disease. In some embodiments, a method for identifying a subject requiring treatment for a risk or presence of metabolic dysfunction or age-related disease is provided, comprising: (a) measuring fatty acid levels in the subject using a high-fidelity fatty acid assay